OBJECTIVES: Malignant tumors of the nasopharynx make up 3% of malignancies in the ENT area. The most common nasopharyngeal malignancy is nasopharyngeal carcinoma (NPC), followed by lymphomas. Other nasopharyngeal tumors are very rare. In this study, we aimed to assess the age distribution and behavior of the primary nasopharyngeal malignancies, NPC, and lymphoma over a ten-year period in a tertiary hospital patient group. DESIGN: Retrospective cohort study. MATERIAL AND METHODS: A total of 48 patients participated in this retrospective monocentric study. The group consisted of 13 females (27.1%) and 35 males (72.9%) diagnosed with nasopharyngeal malignancy and treated between 2012 and 2022. The patients' ages ranged from 14 to 83 years, with a mean age of 57.5 and a median of 55 years. The variables monitored in the study were histology, symptoms (such as nasal obstruction, Eustachian tube function, presence of glue ear, neck mass, weight loss), smoking status, TNM classification, and survival. RESULTS: In NPC grading and staging, two statistically significant variables were found to be associated with survival: distant metastases (p < 0.0001) and stage of the process (p = 0.0153). We did not find age and gender to be significant variables for lymphomas (p = 0.4066; p = 0.1797, respectively) or for NPC (p = 0.8630; p = 0.0573, respectively). Neither did we find any significant cut-off levels. In our analysis of therapy, we discovered that the use of chemoradiotherapy and palliative care in the NPC group is statistically significantly connected with disease-specific survival (p = 0.0094; p = 0.0004). This, however, was not the case in the lymphoma group. For the NPC group, we found statistically significant symptoms only in weight loss (p = 0.0081) and smoking (p = 0.0483). CONCLUSION: Our research confirmed that nasopharyngeal tumors are rare, with the most common type being nasopharyngeal carcinoma. In our patient group, 76.9% of cases involved nasopharyngeal cancer, which was five times more common in men than in women, and typically occurred in individuals over the age of 50. Lymphomas and other tumors accounted for less than a quarter of the cases. The overall five-year survival rate for nasopharyngeal malignancies in our group was 42.3%. We also observed an interesting gender perspective: 75% of women (6 women) survived for five years, whereas 72.2% of men died within five years of diagnosis.

• MeSH
• dospělí MeSH
• karcinom patologie   terapie   epidemiologie   mortalita   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lymfom epidemiologie   terapie   mortalita   MeSH
• mladiství MeSH
• mladý dospělý MeSH
• nádory nosohltanu * terapie   mortalita   patologie   epidemiologie   MeSH
• nasofaryngeální karcinom terapie   mortalita   patologie   MeSH
• retrospektivní studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• staging nádorů MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (27 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2014, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 191 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover endometrial carcinoma staging, definition of prognostic risk groups integrating molecular markers, pre- and intra-operative work-up, fertility preservation, management for early, advanced, metastatic, and recurrent disease and palliative treatment. Principles of radiotherapy and pathological evaluation are also defined.

• Klíčová slova
• Endometrial carcinoma, Guidelines, Management, Molecular markers, Staging,
• MeSH
• biopsie normy   MeSH
• diagnostické techniky molekulární normy   MeSH
• hodnocení rizik MeSH
• karcinom genetika   patologie   terapie   MeSH
• lékařská onkologie normy   MeSH
• lidé MeSH
• medicína založená na důkazech normy   MeSH
• nádorové biomarkery genetika   MeSH
• nádory endometria genetika   patologie   terapie   MeSH
• prediktivní hodnota testů MeSH
• rizikové faktory MeSH
• staging nádorů normy   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• konsensus - konference MeSH
• směrnice pro lékařskou praxi MeSH
• systematický přehled MeSH
• Názvy látek
• nádorové biomarkery MeSH

BACKGROUND: The need for radical surgery followed by adjuvant chemoradiation may be reduced by abandoning radical surgery in patients in whom lymph node involvement is detected intra-operatively. OBJECTIVES: To analyze, in a retrospective cohort study, the efficacy of the algorithm using intra-operative pathological assessment of sentinel lymph nodes. METHODS: A retrospective single-institution study was carried out, which analyzed data from all consecutive patients with cervical cancer who were referred for primary surgical treatment between May 2005 and December 2015. Inclusion criteria were as follows: (1) TNM stage T1a1 with lymphovascular space invasion, T1a2, T1b, T2a, and selected T2b with incipient parametrial invasion; (2) adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma; (3) no evidence of enlarged suspicious nodes or distant metastases on pre-operative imaging; (4) primary surgery with curative intent; (5) successful detection of sentinel lymph node, at least, unilaterally. All patients had at least one sentinel lymph node detected and submitted for frozen section evaluation. When sentinel lymph node involvement was detected intra-operatively, the cervical procedure was abandoned and the patient was referred for definitive chemoradiation. Radical surgery was completed in patients with intra-operative negative sentinel lymph nodes. The reliability of intra-operative sentinel lymph node assessment was evaluated by calculating the sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio. RESULTS: The study included a total of 309 patients. Sentinel lymph nodes were detected bilaterally in 86% of the patients. Lymph node positivity was detected intra-operatively in 18 (6%) patients in whom the cervical procedure was abandoned. Adjuvant radiotherapy after completed radical surgery was given to 29 (9%) patients, including 20 patients with macrometastases (8) or micrometastases (12) reported from the final histology, eight patients with positive parametria (all ≤3 mm), and one patient with a positive vaginal resection margin. The sensitivity, specificity, positive predictive value, and negative predictive value for the intra-operative detection of lymph node positivity (macrometastases or micrometastases) was 47% (95% CI 31% to 64%), 100%, 100%, and 93% (95% CI 90% to 96%), respectively. A total of 18 (6%) patients were spared combined treatment owing to the intra-operative sentinel lymph node triage; 29 patients (9%) received combined treatment with both radical surgery and adjuvant radiotherapy CONCLUSIONS: Of 47 patients with high-risk prognostic risk factors (lymph node, parametria, or surgical margin involvement), combined treatment was successfully avoided in 18 (38%). Despite an effort to triage the patients intra-operatively, 9% received a combination of cervical procedure and adjuvant chemoradiation, mostly owing to the low sensitivity of the frozen section in the detection of micrometastases and macrometastases.

• Klíčová slova
• SLN and lympadenectomy, cervical cancer, postoperative complications, radiation, surgery,
• MeSH
• algoritmy MeSH
• dodržování směrnic statistika a číselné údaje   MeSH
• dospělí MeSH
• karcinom patologie   terapie   MeSH
• kombinovaná terapie statistika a číselné údaje   MeSH
• lidé středního věku MeSH
• lidé MeSH
• lymfatické metastázy MeSH
• nádory děložního čípku patologie   terapie   MeSH
• peroperační péče MeSH
• retrospektivní studie MeSH
• sentinelová uzlina patologie   chirurgie   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

BACKGROUND: Our aim was to identify the number of cases of secretory carcinoma (SC) of the major salivary gland in a population-based cohort and review its clinical behavior with long-term follow-up. METHODS: All malignant salivary gland tumors (MSGTs) diagnosed between 1980 and 2014 were assessed for histological features compatible with SC and 140 were selected for further analysis. RESULTS: Twenty two new cases of SC were identified, 19 of which were originally classified as acinic cell carcinoma, and 3 as adenocarcinoma, not otherwise specified (NOS). Lymph node involvement was less common in SC tumors (5%) than in the control group (11%). Disease recurrence was seen less frequently in SC (9%) than the control group (20%). Mean disease-free survival was 192 months for SC compared with 162 months for controls (P = 0.15). CONCLUSION: The clinical course of SC is typically indolent with a low risk of relapse not significantly different from other low-grade MSGT.

• Klíčová slova
• ETV6, MASC, head and neck surgery, mammary analog secretory carcinoma, salivary gland tumors,
• MeSH
• acinární karcinom epidemiologie   patologie   MeSH
• adenokarcinom epidemiologie   patologie   MeSH
• analýza přežití MeSH
• dospělí MeSH
• karcinom * epidemiologie   patologie   terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory slinných žláz * epidemiologie   patologie   terapie   MeSH
• následné studie MeSH
• registrace MeSH
• retrospektivní studie MeSH
• studie případů a kontrol MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH

BACKGROUND: Previous results from the GEC-ESTRO trial showed that accelerated partial breast irradiation (APBI) using multicatheter brachytherapy in the treatment of early breast cancer after breast-conserving surgery was non-inferior to whole-breast irradiation in terms of local control and overall survival. Here, we present 5-year results of patient-reported quality of life. METHODS: We did this randomised controlled phase 3 trial at 16 hospitals and medical centres in seven European countries. Patients aged 40 years or older with 0-IIA breast cancer were randomly assigned (1:1) after breast-conserving surgery (resection margins ≥2 mm) to receive either whole-breast irradiation of 50 Gy with a boost of 10 Gy or APBI using multicatheter brachytherapy. Randomisation was stratified by study centre, tumour type, and menopausal status, with a block size of ten and an automated dynamic algorithm. There was no masking of patients or investigators. The primary endpoint of the trial was ipsilateral local recurrence. Here, we present 5-year results of quality of life (a prespecified secondary endpoint). Quality-of-life questionnaires (European Organisation for Research and Treatment of Cancer QLQ-C30, breast cancer module QLQ-BR23) were completed before radiotherapy (baseline 1), immediately after radiotherapy (baseline 2), and during follow-up. We analysed the data according to treatment received (as-treated population). Recruitment was completed in 2009, and long-term follow-up is continuing. The trial is registered at ClinicalTrials.gov, number NCT00402519. FINDINGS: Between April 20, 2004, and July 30, 2009, 633 patients had accelerated partial breast irradiation and 551 patients had whole-breast irradiation. Quality-of-life questionnaires at baseline 1 were available for 334 (53%) of 663 patients in the APBI group and 314 (57%) of 551 patients in the whole-breast irradiation group; the response rate was similar during follow-up. Global health status (range 0-100) was stable in both groups: at baseline 1, APBI group mean score 65·5 (SD 20·6) versus whole-breast irradiation group 64·6 (19·6), p=0·37; at 5 years, APBI group 66·2 (22·2) versus whole-breast irradiation group 66·0 (21·8), p=0·94. The only moderate, significant difference (difference of 10-20 points) between the groups was found in the breast symptoms scale. Breast symptom scores were significantly higher (ie, worse) after whole-breast irradiation than after APBI at baseline 2 (difference of means 13·6, 95% CI 9·7-17·5; p<0·0001) and at 3-month follow-up (difference of means 12·7, 95% CI 9·8-15·6; p<0·0001). INTERPRETATION: APBI with multicatheter brachytherapy was not associated with worse quality of life compared with whole-breast irradiation. This finding supports APBI as an alternative treatment option after breast-conserving surgery for patients with early breast cancer. FUNDING: German Cancer Aid.

• MeSH
• adjuvantní radioterapie MeSH
• brachyterapie škodlivé účinky   metody   MeSH
• časové faktory MeSH
• dospělí MeSH
• karcinom patologie   terapie   MeSH
• kvalita života * MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory prsu patologie   terapie   MeSH
• průzkumy a dotazníky MeSH
• segmentální mastektomie * škodlivé účinky   MeSH
• senioři MeSH
• staging nádorů MeSH
• stupeň nádoru MeSH
• výsledek terapie MeSH
• zdravotní stav MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH
• Geografické názvy
• Evropa MeSH

Salivary gland neoplasms are a morphologically heterogenous group of lesions that are often diagnostically challenging. In recent years, considerable progress in salivary gland taxonomy has been reached by the discovery of tumor type-specific fusion oncogenes generated by chromosome translocations. This review describes the clinicopathologic features of a selected group of salivary gland carcinomas with a focus on their distinctive genomic characteristics. Mammary analog secretory carcinoma is a recently described entity characterized by a t(12;15)(p13;q25) translocation resulting in an ETV6-NTRK3 fusion. Hyalinizing clear cell carcinoma is a low-grade tumor with infrequent nodal and distant metastasis, recently shown to harbor an EWSR1-ATF1 gene fusion. The CRTC1-MAML2 fusion gene resulting from a t(11;19)(q21;p13) translocation, is now known to be a feature of both low-grade and high-grade mucoepidermoid carcinomas associated with improved survival. A t(6;9)(q22-23;p23-34) translocation resulting in a MYB-NFIB gene fusion has been identified in the majority of adenoid cystic carcinomas. Polymorphous (low-grade) adenocarcinoma and cribriform adenocarcinoma of (minor) salivary gland origin are related entities with partly differing clinicopathologic and genomic profiles; they are the subject of an ongoing taxonomic debate. Polymorphous (low-grade) adenocarcinomas are characterized by hot spot point E710D mutations in the PRKD1 gene, whereas cribriform adenocarcinoma of (minor) salivary glands origin are characterized by translocations involving the PRKD1-3 genes. Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma with morphologic and molecular features akin to invasive ductal carcinoma of the breast, including HER2 gene amplification, mutations of TP53, PIK3CA, and HRAS and loss or mutation of PTEN. Notably, a recurrent NCOA4-RET fusion has also been found in SDC. A subset of SDC with apocrine morphology is associated with overexpression of androgen receptors. As these genetic aberrations are recurrent they serve as powerful diagnostic tools in salivary gland tumor diagnosis, and therefore also in refinement of salivary gland cancer classification. Moreover, they are promising as prognostic biomarkers and targets of therapy.

• MeSH
• biopsie MeSH
• diagnostické techniky molekulární * MeSH
• diferenciální diagnóza MeSH
• fenotyp MeSH
• fúze genů MeSH
• genetická predispozice k nemoci MeSH
• karcinom genetika   patologie   terapie   MeSH
• lidé MeSH
• mutace MeSH
• nádorové biomarkery genetika   MeSH
• nádory slinných žláz genetika   patologie   terapie   MeSH
• prediktivní hodnota testů MeSH
• stupeň nádoru MeSH
• translokace genetická MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• nádorové biomarkery MeSH

CONTEXT: The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. OBJECTIVE: To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: urinary tract cancer; urothelial carcinomas; upper urinary tract, carcinoma; renal pelvis; ureter; bladder cancer; chemotherapy; ureteroscopy; nephroureterectomy; adjuvant treatment; instillation; recurrence; risk factors; and survival. References were weighted by a panel of experts. EVIDENCE SYNTHESIS: Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing number of retrospective articles in UTUC. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification, as well as for radical and conservative treatment; prognostic factors are also discussed. A single postoperative dose of intravesical mitomycin after radical nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumours and two functional kidneys. CONCLUSIONS: These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. PATIENT SUMMARY: Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis; appropriate diagnosis and management is most important. We present recommendations based on current evidence for optimal management.

• Klíčová slova
• Cytology, Guidelines, Nephroureterectomy, Renal pelvis, Risk factors, Survival, Ureter, Ureteroscopy, Urinary tract cancer, Urothelial carcinoma,
• MeSH
• karcinom diagnóza   mortalita   terapie   MeSH
• klinické rozhodování MeSH
• konsensus MeSH
• lidé MeSH
• medicína založená na důkazech normy   MeSH
• rizikové faktory MeSH
• staging nádorů MeSH
• urologické nádory diagnóza   mortalita   terapie   MeSH
• urologie normy   MeSH
• urotel patologie   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• směrnice pro lékařskou praxi MeSH

Reassessment of histological specimens of salivary gland carcinomas is associated with a change of primary diagnosis in a significant number of patients. The authors evaluated the relation between reclassification/verification of histological diagnosis and the clinical course of parotid gland carcinomas. Histological and immunohistochemical examinations of 111 specimens of parotid gland carcinomas operated on during the years 1992-2010 were revised and in some cases supplemented with cytogenetic tests (FISH), to verify the diagnosis and potentially reclassify the tumours. Analysis of the clinical documentation and follow-up data of patients whose diagnosis was changed was then carried out. The prognostic factors taken into account in the evaluation of the clinical course included the T and N stage, the tumour grade and the extent of resection. The primary diagnosis was changed on review in 28 patients (25.2 %). In 16 patients, the change involved a different histological type of cancer. In six cases, what was thought to be a primary salivary gland cancer was reclassified as a secondary tumour. In four other cases, the change was made from a malignant to a benign tumour and in one case to a non-neoplastic lesion (necrotizing sialometaplasia). Additionally, in two patients with carcinoma ex pleomorphic adenoma, the malignant component was found to be of in situ type. A potentially atypical clinical course was observed in 4 out of 28 patients whose diagnosis was changed. In the case of 2 patients, the course of disease was more aggressive (dissemination, death) than predicted and less aggressive in rest of the patients. Histological reclassification/verification of parotid gland carcinomas can explain the cause of an atypical clinical course in some patients and sometimes enables doctors to implement a change in therapy.

• Klíčová slova
• Clinical course, Histopathology, Parotid gland carcinoma, Revision,
• MeSH
• dospělí MeSH
• karcinom klasifikace   patologie   terapie   MeSH
• kohortové studie MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory příušní žlázy klasifikace   patologie   terapie   MeSH
• parotis patologie   MeSH
• pleomorfní adenom klasifikace   patologie   terapie   MeSH
• senioři MeSH
• staging nádorů MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

Pregnancy-associated breast cancer is defined as carcinoma diagnosed during pregnancy or breastfeeding, up to a year after delivery. Pregnant patients with breast cancer can be treated using procedures for non-pregnant patients, with some modifications designed to avoid damage to the fetus. Breastfeeding breast cancer patients need to stop immediately. Abortion before start of treatment or during therapy does not increase survival of these patients. Chemotherapy of breast cancer may start roughly from the second month of pregnancy. Effective treatment with anthracyclines, taxanes, and cisplatin is relatively safe for both mother and fetus. During pregnancy, patients can undergo surgery but are unable to undergo radiotherapy. Also, hormonal therapy and trastuzumab treatment is not safe for pregnant women with breast cancer. Prognosis of pregnant breast cancer patients is similar to non-pregnant patients. Worse prognosis was noted for breast cancer patients diagnosed during breastfeeding. After the cancer treatment is finished, breastfeeding is completely safe, but technical reasons it can usually only be done using the contra-lateral breast. Children of mothers who were treated for breast cancer during pregnancy do not show any worsening of physical and psychiatric parameters of development. Pregnancy following treatment for breast cancer does not affect the patients prognosis in a negative way, according to clinical studies, not even in patients who suffered from a hormonal-dependent carcinoma.Key words: breast cancer - pregnancy - breastfeeding - chemotherapy - radiotherapy - biological treatment - hormonal therapyThe author declares she has no potential conflicts of interest concerning drugs, products, or services used in the study.The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 10. 7. 2016Accepted: 20. 7. 2016.

• MeSH
• karcinom terapie   MeSH
• kojení * MeSH
• lidé MeSH
• nádorové komplikace v těhotenství terapie   MeSH
• nádory prsu terapie   MeSH
• prognóza MeSH
• těhotenství MeSH
• výsledek těhotenství MeSH
• Check Tag
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

Incidence of differentiated thyroid carcinomas, especially papillary carcinomas, in recent decades worldwide increase. This is especially the detection of small tumor sizes up to two centimeters. Causes of the increase of these cancers are either increased number of thyroid investigations, but also the actual increase of this disease. The subject of expert discussion on this topic is mainly assessment of the severity of newly diagnosed tumors, the choice of treatment strategy and choice of follow-up of patients. Given that a large part of tumor detected in an early stage and due to the success of the current treatment options for the prognosis of thyroid cancer is usually good. Despite the large increase of the incidence, mortality for this type of cancer, in countries with good individualized treatment, decreases. We present a review of literature on the topic.Key words: thyroid carcinoma - post-operation monitoring - radioiodine - stratification of the risk of relapse.

• MeSH
• časná detekce nádoru MeSH
• časná lékařská intervence MeSH
• incidence MeSH
• karcinom epidemiologie   terapie   MeSH
• lidé MeSH
• lokální recidiva nádoru epidemiologie   MeSH
• nádory štítné žlázy epidemiologie   terapie   MeSH
• následná péče MeSH
• papilární karcinom štítné žlázy MeSH
• papilární karcinom MeSH
• prognóza MeSH
• radioizotopy jodu terapeutické užití   MeSH
• tyreoidektomie * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• radioizotopy jodu MeSH